Business Wire

ExThera Medical Receives CE Mark Approval for the Seraph® 100 Blood Filter

Share

ExThera Medical Corporation (ExThera) announced today that it has received CE Mark approval for its Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) for the reduction of pathogens during bloodstream infections (BSI). This CE Mark signifies that Seraph 100 meets the safety and performance requirements for medical devices in the European Economic Area (EEA) as an adjunct to anti-infective therapy, and it gives ExThera access to a market of 500 million people. In October 2019 ExThera plans to begin shipping Seraph 100 for clinical use in selected member states of the European Union, providing a completely new treatment option for a large, at-risk patient population. Distributors for Italy, Germany and other EU countries will be announced early in September.

Bloodstream infections are a leading cause of death around the world, with mortality as high as 50%.i In Europe, the annual incidence rate is estimated at 1.2 million.ii In addition to rapid diagnostic tests, quick and effective therapeutic products are needed to successfully treat these infections for which every hour of delay in effective treatment can increase mortality by up to 7%.iii The challenge of quickly reducing pathogens is severely complicated during increasingly common drug-resistant infections, which are estimated to kill 10 million people annually by 2050.iv

As a broad-spectrum ‘sorbent-type blood filter’ Seraph 100 provides a new option for treating bloodstream infections. Whereas existing devices remove only molecules, e.g. cytokines and/or endotoxin, Seraph 100 can also quickly lower the concentration of bacteria, viruses and fungi in whole blood. In pre-clinical and clinical testing, Seraph 100 was able to significantly reduce the concentration of both drug-susceptible and drug-resistant pathogens, providing a long-awaited adjunctive therapy for bloodstream infections.

In March, 2019, Dr. med. Stefan Büttner of the Department of Nephrology, Dialysis and Kidney Transplantation at University Hospital Frankfurt, presented research findings at the International Symposium on Intensive Care and Emergency Medicine (ISICEM), highlighting Seraph 100's excellent clinical results, including the safe treatment of bacteremia during dialysis.

Today marks a definitive turning point in advancing the care of bloodstream infections, the result of years of dedicated research, development and investment,” according to Bob Ward, NAE, President / CEO of ExThera. “Seraph 100 provides an innovative therapy for rapid and effective treatment of infections that might otherwise pose a devastating risk to patients. We look forward to Seraph 100’s continued success in Europe, while demonstrating its potential to help healthcare providers and their patients around the world.”

Bloodstream infections pose a continuing challenge for healthcare providers worldwide, with the threat of catastrophic consequences for the patient, often leading to sepsis and even death if not treated effectively,” said Prof. Dr. med Jan T. Kielstein, FASN, FERA, Director, Medical Clinic V: Nephrology, Rheumatology and Blood Purification, Academic Teaching Hospital Braunschweig, Germany. “Seraph 100 adds a critical tool to our clinical arsenal that can be used to treat a wide range of infections, including those that are proven to be drug-resistant. It’s an option we were not previously able to employ, and we are excited to have it available.”

According to consultant Kathleen White, ExThera’s former V.P. and Chief Operating Officer, “The ExThera team did an extraordinary job designing, testing and obtaining regulatory approval for Seraph 100, while also gaining certification of its Quality Management System. I thank them, our consultants and our clinical collaborators for their hard work and dedication to this revolutionary product.”

About Seraph and ExThera Medical

Based in the San Francisco Bay Area, and in Vaals, The Netherlands, ExThera is a privately held medical device company developing innovative, single-use blood filters capable of capturing a broad range of pathogens from whole blood. Seraph’s unique design, and its highly blood-compatible surface, first developed at Stockholm‘s Karolinska Institutev, quickly reduces the concentration of drug-resistant and drug-susceptible bacteria, viruses, fungi and sepsis mediators in blood continuously drawn from, and returned to the patient. ExThera develops therapeutic products to treat patients in the hospital, on the battlefield and during epidemics. Led by an accomplished management team with extensive experience in blood-contacting devices and biomaterials, the company has worldwide patent protection and a growing body of data from independent laboratory studies, including as best performer in DARPA’s Dialysis-Like Therapeutics program, and from its successful EU clinical trial.

For more information, please visit www.extheramedical.com.

Disclaimer: All information contained in this news release derives from plausible reliable sources, which, however, have not been independently examined. There is no warranty, confirmation or guarantee, and no responsibility or liability is taken concerning correctness or completeness. As far as it is allowed by the relevant law, no liability whatsoever is taken on for any direct or indirect loss caused by the deployment of this news release or its contents. This communication includes forward-looking statements regarding events, trends and business prospects that may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. The investment and/or the revenues that arise from it can rise or fall. A total loss is possible. Persons who are in possession of this news release are requested to obtain information concerning possible legal limitations and to observe them accordingly. We assume no responsibility to update or revise any forward-looking statements contained in this news release to reflect events, trends, or circumstances after the date of this news release.


i Neuner, Elizabeth A., et al. "Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections." Diagnostic microbiology and infectious disease 69.4 (2011): 357-362.

ii Goto, M., and M. N. Al‐Hasan. "Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe." Clinical Microbiology and Infection 19.6 (2013): 501-509.

iii Kumar, A. et.al. “Duration of Hypotension Before Initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock”, Crit. Care Medicine, 2006;34(6):1589-1596.

iv Review on Antimicrobial Resistance. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. 2014.

v Larm O, Larsson R, Olsonn P (1983) A new non-thrombogenic surface prepared by selective covalent binding of heparin…. Biomater Med Devices Artif Organs 11: 161– 173.

Contact information

ExThera Medical Europe
Carla Kikken-Jussen
carla@extheramedical.com

ExThera Medical USA
Galit Gelman
Galit@extheramedical.com

Media
Heather Linville
media@extheramedical.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IFF Declares Dividend for Fourth Quarter 201912.12.2019 00:15:00 EETPress release

Regulatory News: IFF (NYSE:IFF) (Euronext Paris:IFF) (TASE:IFF), a leading innovator of taste, scent and nutrition announced that its Board of Directors has declared a regular quarterly cash dividend of $0.75 per share of its common stock, payable on January 7, 2020 to shareholders of record as of December 27, 2019. Welcome to IFF At IFF (NYSE:IFF) (Euronext Paris:IFF) (TASE:IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com, Twitter , Facebook, Instagram, and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20191211005907/en/ Contact information Michael DeVeau Head of Investor Relations and Communications & Divisional CFO, Scent 212.708.7164 Michael.DeVeau@iff.com

Kite Submits Biologics License Application to U.S. Food and Drug Administration for Company’s Second CAR T Cell Therapy12.12.2019 00:05:00 EETPress release

Kite, a Gilead Company (Nasdaq: GILD), today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the investigational chimeric antigen receptor (CAR) T cell therapy, KTE-X19, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). The BLA submission is based on data from the Phase 2 ZUMA-2 trial, which demonstrated an overall response rate of 93 percent, including 67 percent with complete response, as assessed by an Independent Radiologic Review Committee (IRRC) following a single infusion of KTE-X19. In the safety analysis, Grade 3 or higher cytokine release syndrome (CRS) and neurologic events were seen in 15 percent and 31 percent of patients, respectively. No Grade 5 CRS or neurologic events occurred. Detailed findings from this trial were recently presented at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando. “There remains a significant need

PTW International Announces Orange Rock Studios, Their Product and Game Development Arm11.12.2019 20:00:00 EETPress release

Pole to Win International, Ltd. (PTW), the industry-leading video games and tech services outsourcer, today announced the launch of its product and game development arm, Orange Rock Studios. Orange Rock Studios will enhance the service offering of PTW, a gaming industry stalwart with an established and diverse dossier of top-tier clients across multiple verticals. “The time to be disruptive is now,” said Deborah Kirkham, CEO of PTW. “At Orange Rock, we foster future technologies to anchor projects with ingenuity and discipline for generation Y and Z. Together with our clients, we envision and engineer digital experiences.” “Orange Rock is the engine that will build PTW’s future by enabling us to bring each of our existing service lines - Quality Assurance, Customer Support, Audio Production, Localization, and Translation - to the forefront of their fields through cutting edge in-house tool development. We will deliver the creative products that accelerate our industry’s progress toward

Fastly Shares the Most Notable Internet Infrastructure Milestones of 2019, and What 2020 Might Bring for the Expansion of Platform-Independent Computing11.12.2019 19:30:00 EETPress release

Fastly, Inc. (NYSE: FSLY), provider of a global edge cloud platform, today released its “Behind the Screens” retrospective detailing 2019’s notable milestones in internet infrastructure, from the increased adoption of modernized protocols, to the growth in reach and capacity of global high-speed internet, and more. Fastly’s CTO and co-founder, Tyler McMullen, anticipates that these advancements, combined with the rise of WebAssembly and the extension of code portability across platforms and devices, set the programming world up for achieving broader value from serverless computing. The State of Internet Infrastructure in 2019 This year saw a groundswell of grassroots protocol improvements, sweeping shifts toward encryption due to increased focus on data privacy, and a preview into WebAssembly’s possibilities at the edge, as well as: New satellites that took to the sky and submarine cables that were installed to grow capacity around the globe. Congestion control reimagined through BBR,

Invicro Supports the Alzheimer’s Disease Neuroimaging Initiative11.12.2019 18:37:00 EETPress release

Invicro LLC, a Konica Minolta Company, today announced funding support for the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and two of their distinguished scientists within the Alzheimer’s biomarkers space, Drs. Roger Gunn and Kenneth Marek, will join the ADNI-Private Partner Scientific Board (PPSB). Invicro is a global provider of imaging biomarkers, core lab services, advanced analytics and software solutions for drug discovery and development. ADNI is a longitudinal multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer’s disease (AD). ADNI’s mission strives to detect AD at the earliest stage possible (pre-dementia) and identify ways to track the disease’s progression with biomarkers, as well as support advances in AD intervention, prevention, and treatment. “Invicro is delighted to support ADNI which plays a central role in the development of biomarkers that enable advances in AD interven

Sevan Elevate Brings Safety and Sustainability to New Heights11.12.2019 17:00:00 EETPress release

Sevan Multi-Site Solutions, Inc. (Sevan), a global leader in data analytics, surveys, design, program management and construction services, is excited to announce the launch of Sevan Elevate, a program that will reinforce and continuously improve Safety and Sustainability across the company to deliver excellence to people and clients. Safety and Sustainability have been a strategic imperative since 2011 when Sevan was founded by a handful of entrepreneurs, including President and CEO Jim Evans. “Sevan’s tenets are Safety and Sustainability—both of which are woven through every element of the company. It is imperative that all our people—including team members, clients and business partners—return home safely to their loved ones at the end of the day,” Evans said. “With Sevan Elevate, the company is more committed than ever to raise awareness and compliance of Safety and Sustainability throughout the multi-site construction world. We’re not going to change the world overnight, but we ca

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom